Keros Therapeutics Inc
$ 14.19
-5.59%
27 Feb - close price
- Market Cap 432,314,000 USD
- Current Price $ 14.19
- High / Low $ 15.11 / 13.97
- Stock P/E 9.10
- Book Value 17.32
- EPS 1.56
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.10 %
- 52 Week High 22.55
- 52 Week Low 9.12
About
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$23.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-04 | 2024-08-06 | 2024-05-08 | 2024-02-28 | 2023-11-06 | 2023-08-07 | 2023-05-04 | 2023-03-03 |
| Reported EPS | -0.18 | -0.76 | 3.62 | -1.14 | -1.41 | -1.25 | -1.21 | -1.34 | -1.33 | -1.27 | -1.26 | -1.09 |
| Estimated EPS | -1.05 | -1.13 | 0.0075 | -0.427 | -1.28 | -1.23 | -1.35 | -1.37 | -1.35 | -1.34 | -1.12 | -1.1 |
| Surprise | 0.87 | 0.37 | 3.6125 | -0.713 | -0.13 | -0.02 | 0.14 | 0.03 | 0.02 | 0.07 | -0.14 | 0.01 |
| Surprise Percentage | 82.8571% | 32.7434% | 48166.6667% | -166.9789% | -10.1563% | -1.626% | 10.3704% | 2.1898% | 1.4815% | 5.2239% | -12.5% | 0.9091% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.6963 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KROS
2026-02-28 17:52:32
Keros Therapeutics announced plans to initiate a Duchenne muscular dystrophy (DMD) trial for rinvatercept (KER-065) this quarter and to discuss a potential Phase II program in amyotrophic lateral sclerosis (ALS) with regulators later this year. The company's CEO, Jasbir Seehra, highlighted rinvatercept's mechanism as a modified activin-receptor ligand trap that inhibits negative muscle regulators and showed positive pharmacology signals in Phase I trials, including increased lean mass and improved bone markers. Keros also reviewed its partnership with Takeda for elritercept, which includes significant upfront payments and potential milestones.
2026-02-28 10:52:33
This article provides an analysis of Keros Therapeutics Inc. (NASDAQ: KROS), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report suggests potential for lower levels if the current breakdown is sustained and points to elevated downside risk.
2026-02-27 22:04:56
Keros Therapeutics (KROS) has appointed Charles Newton, former CFO of Lyell Immunopharma and a veteran healthcare investment banker, as a Class III director, effective March 9, 2026. Newton will also join the Compensation and Audit Committees, bringing extensive financial and capital markets expertise to support Keros's clinical pipeline. This appointment coincides with long-serving director Carl Gordon stepping down from the board.
2026-02-27 13:51:56
Western Standard LLC significantly increased its stake in Keros Therapeutics (NASDAQ:KROS) by 42.7% in Q3, making it the fund's largest holding at 10.3% of its portfolio. This accumulation brings Western Standard's total KROS shares to 2,189,882, valued at $34.64 million, representing about 7.19% of Keros. Despite institutional ownership being high (71.56%), analysts maintain a consensus "Hold" rating with a price target of $22.29 for the stock, which is currently trading near $15.03.
2026-02-26 22:52:33
Keros Therapeutics announced the appointment of finance veteran Charles Newton to its board of directors and key committees, effective March 9, 2026. This move, which includes Newton joining the Compensation and Audit Committees, coincides with longtime director Carl Gordon's planned resignation. Newton's appointment is expected to provide valuable healthcare finance and capital markets experience as Keros advances its clinical pipeline, including rinvatercept.
2026-02-26 22:52:32
Keros Therapeutics has announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. Newton brings extensive experience in healthcare finance and capital markets, having previously served as CFO of Lyell Immunopharma and held leadership roles at major investment banks. Concurrently, Carl Gordon, Ph.D., CFA, will be stepping down from the board.
